

COPY

SHEET 1 OF 8

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellestrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown 1642

11046 U.S. PTO
10/076306
02/12/02

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
KAC ALH	5,348,739	09-1994	Hellestrand et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
KAC ALH	JP 7-185582	08/27/85	Japan (with English translation in 15 pages)				
KAC ALH	WO 93/24144	12/09/93	Patent Cooperation Treaty				
KAC	0 247 613 A2	12/02/87	European Patent Office				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
KAC ALH	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
KAC ALH	Abrams, et al., "High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
KAC duplicate	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- γ , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- α , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
KAC duplicate	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
KAC duplicate	Abrams, et al., "High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
KAC ALH	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- γ , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- α , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
KAC ALH	Baker, et al., "Chondrocyte Antioxidant Defenses: The Roles of Catalase and Glutathione Peroxidase in Protection Against H ₂ O ₂ Dependent Inhibition of Proteoglycan Biosynthesis," <i>The Journal of Rheumatology</i> , 15: No. 4, 670-677, 1988.
KAC ALH	Barna, et al., "Tumor-Enhancing Effects of Cimetidine," <i>Oncology</i> , 40: 43-45, (1983).
KAC ALH	Beer, et al., The Influence of Histamine on Immune and Inflammatory Responses, <i>Advances in Immunology</i> , 35: 209-268 (1984).

EXAMINER	<i>William D. Gault</i>	DATE CONSIDERED	10/31/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

BEST AVAILABLE COPY

JAN 07 2005

SHEET 2 OF 8

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MARIM 28C3APPLICATION NO.
UnknownINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hellstrand, et al.FILING DATE
February 12, 2002GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
attached	Brune, et al., "Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia," <i>British Journal of Haematology</i> , 92:620-626 (1996).
KAC ✓ ACH	Budd, et al., "Phase I Trial of High-Dose Bolus Interleukin-2 and Interferon Alfa-2a in Patients With Metastatic Malignancy," <i>Journal of Clinical Oncology</i> , 10: No. 5, 804-809, May 1992.
KAC ✓ ACH	Burtin, et al., "Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H2-Antihistaminics" (Ranitidine or Cimetidine), Accepted June 1987.
attached	Burtin, et al., "The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice", <i>Cancer Letters</i> , 12: 195-201, (1981).
attached	Chaudhri, et al., "Antioxidants Inhibit Proliferation and Cell Surface Expression of Receptors for Interleukin-2 and Transferrin in T Lymphocytes Stimulated with Phorbol Myristate Acetate and Ionomycin" <i>Cellular Immunology</i> , 115:204-213 (1988).
KAC ✓ ACH	Chehimi, et al., "Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-infected Patients," <i>Journal of Experimental Medicine</i> , 175: 789-796, March 1992.
KAC ✓ ACH	Ching, et al., "In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthene Analogues of Flavone Acetic Acid," <i>Eur. J. Cancer</i> , 27: No. 12, 1684-1689, 1991.
KAC ✓ ACH	Ching, et al., "Induction of Natural Killer Activity by Xanthene Analogues of Flavone Acetic Acid: Relation with Antitumour Activity," <i>Eur. J. Cancer</i> , 27: No. 1, 79-83, 1991.
ACH	Damia, et al., "Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells," <i>Cancer Immunol Immunother</i> , 32: 241-244, 1990.
ACH	Davies, et al., "Interactions between human monocytes and tumor cells. Monocytes can either enhance or inhibit the growth and survival of K562 Cells," November 1991.
ACH	Dempsey, et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity," <i>The Journal of Immunology</i> , May 17, 1982.
ACH	Dillman, et al., "Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial," <i>Journal of Clinical Oncology</i> , 9: No. 7, 1233-1240, July 1991.
ACH	Dilman, et al., "Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial," <i>Journal of the National Cancer Institute</i> , 82: No. 16, 1345-1348, August 15, 1990.
ACH	Dohlsten, et al., "Histamine Inhibits Interferon- Production via Suppression of Interleukin 2 Synthesis," <i>Cellular Immunology</i> , 101: 493-501, 1986.
ACH	Dröge, et al., "Effect of Reactive Oxygen Intermediates and Antioxidants on Proliferation and Function of T Lymphocytes" <i>Methods in Enzymology</i> , 234:135-151 (1994).
ACH	Dröge, et al., "Histamine Augments Interleukin-2 Production and the Activation of Cytotoxic T Lymphocytes," <i>Immunopharmacology</i> , 11: 1-6, 1986.
✓ ACH	Dutcher, et al., "A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients With Metastatic Melanoma," <i>Journal of Clinical Oncology</i> , 9: No. 4, 641-648, April 1991..

EXAMINER

Harm A. Lancelli

DATE CONSIDERED

10/31/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

BEST AVAILABLE COPY

JAN 07 2005

SHEET 3 OF 8

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MPEP 28C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Aut	Duwe, et al., "Natural Killer Cell-Mediated Lysis Involves an Hydroxyl Radical-Dependent Step," <i>The Journal of Immunology</i> , 134: No. 4, 2637-2644, April 1985.
Aut	El-Hag, et al., "Down-Regulation of Human Natural Killer Activity Against Tumors by the Neutrophil Myeloperoxidase System and Hydrogen Peroxide," <i>The Journal of Immunology</i> 133: No. 6, 3291-3297, December 1984.
attached	Froelich, et al., "Induction of lymphokine activated killer cells in serum-free medium" <i>Journal of Immunological Methods</i> , 86:205-211, No. 2 (1986).
Aut	Galligioni, "Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with Flavone acetic acid (FAA)," <i>Annals of Oncology</i> , 2: 145-150, 1991.
Aut	Hellstrand, "Biogenic Amines in the Regulation of Human Natural Killer Cell Cytotoxicity," 1987.
attached	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
Aut	Hellstrand, et al., "A Cell-to-Cell Mediated Interaction Involving Monocytes and Non-T/CD16 ⁺ Natural Killer (NK) Cells is Required for Histamine H ₂ -Receptor-Mediated NK-Cell Activation," <i>Scand J. Immunol</i> , 31: 631-644, 1990.
Aut	Hellstrand, et al., "Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H ₂ -Receptors," <i>Scand J. Immunol</i> , 34: 741-752, 1991..
Aut	Hellstrand, et al., "Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Cell Activity," <i>Int. Archs Allergy appl. Immunology</i> , 84: 247-255, 1987.
Aut	Hellstrand, et al., "Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD16 ⁺ NK Cells, Accessory Monocytes, and 5-HT _{1A} Receptors," <i>Cellular Immunology</i> , 127: 199-214, 1990.
Aut	Hellstrand, et al., "Histamine H ₂ -Receptor-Mediated Regulation of Human Natural Killer Cell Activity," <i>The Journal of Immunology</i> , 137: No. 2, July 15, 1986.
Aut	Hellstrand, et al., "Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H ₂ -Receptors," <i>Cellular Immunology</i> , 138: 44-45, 1991..
Aut	Hellstrand, et al., "Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation," <i>Scand J. Immunol</i> , 32: 183-192, 1990.
Aut	Hellstrand, et al., "Regulation of the Natural Killer Cell Response to Interferon- by Biogenic Amines," <i>Journal of Interferon Research</i> , 12: 199-206, 1992.
Aut	Hellstrand, et al., "Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells," <i>The Journal of Immunology</i> , 145: No. 12, December 15, 1990.
Aut	Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," <i>The Journal of Immunology</i> , 139: No. 3, August 1, 1987
Aut	Hellstrand, et al., "Serotonergic 5-HT _{1A} Receptors Regulate a Cell Contact-Mediated Interaction between Natural Killer Cells and Monocytes," <i>Scand J. Immunol</i> , 37: 7-18, 1993
duplicate	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
Aut	Hellstrand, et al., "Suppression of human natural killer cell cytotoxicity by interleukin-2," <i>Clin. Exp. Immunol</i> , 77: 410-416, 1989

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

BEST AVAILABLE COPY

JAN 07 2005

SHEET 4 OF 6

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MA98026C3APPLICATION NO.
UnknownINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hallstrand, et al.FILING DATE
February 12, 2002GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Aut	Hellstrand, et al., "Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2," <i>Int. Arch. Allergy Appl. Immunology</i> , 92: 379-389, 1990.
attached	Histamine augments interleukin-2 production and the activation of cytotoxic T lymphocytes, <i>Chemical Abstracts</i> , 104: Number 146898m, page 146891.
Aut	Hornung, et al., "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2," <i>The Journal of Immunology</i> , 141: No. 10, 3671-3679, November 15, 1988.
Aut	Huwylar, et al., "Effect of Ascorbic Acid on Human Natural Killer Cells," <i>Immunology Letters</i> , 10: 173-176, 1985.
Aut	Ison, et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients With Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1124-1130, July 1992.
Aut	Kendall A. Smith, "Interleukin-2: Inception, Impact, and Implications," <i>Science</i> , 240: 1169-1176, May 27, 1988.
Aut	Kessel, et al., "Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations," <i>Immunology</i> , 58: 291-296, 1986.
Aut	Khoo, et al., "Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2," <i>Clin. Exp. Metastasis</i> , 10: 239-252, 1992.
Aut	Krigel, et al., "enal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon," <i>Journal of Clinical Oncology</i> , 8: No. 3, 460-467, March 1990.
Aut	Lasek, et al., "Potentiation of antitumor effects of tumor necrosis factor γ and interferon (by macrophage-colony-stimulating factor in a MnB16 melanoma model in mice" <i>Cancer Immunol Immunother</i> 40:315-321 (1995).
Aut	Lepinat, et al., "Enhancement by serotonin of intra-tumour penetration of spleen cells," <i>Br. J. Cancer</i> , 50: 545-547, (1984).
attached	Los, et al., "Hydrogen peroxide as a potent activator of T lymphocyte functions" <i>Eur. Journal of Immunology</i> , 25:159-165 (1995).
Aut	Lotze, et al., "Interleukin 2 as a Pharmacologic Reagent, Chapter 12 from the National Institutes of Health," October 28, 1988.
attached	Malech, et al., "Peptide derivative cytochrome inhibit enzyme system oxidation burst phagocyte cell inflammation disease" DABASE WPI/DERWENT (Abstract) (1989).
Aut	Mavligit, et al., "plenic Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases," <i>Journal of Clinical Oncology</i> , 8: No. 2, 319-324, 1990.
Aut	Mertens, et al., "Sustained Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A Phase II Study," <i>Clinical Oncology</i> , 5: No. 2, 107-113, 1993.
Aut	Middleton, et al., "Effects of Flavonoids on Immune and Inflammatory Cell Functions," <i>Biochemical Pharmacology</i> , 43: No. 6, 1167-1179, 1992.
Aut	Munakata, et al., "Induction of Interferon- Production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide," <i>The Journal of Immunology</i> , 134: No. 4, 2449-2455, April 1985.

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

BEST AVAILABLE COPY

JAN 07 2005

SHEET 5 OF 8

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. F.M.A. 26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILED DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ArH	Nabil Hanna, "The Role of Natural Killer Cells in the Control of Tumor Growth and Metastasis," <i>Biochimica et Biophysica Acta</i> , 780: 213-226, 1985.
ArH	Nair, et al., "Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2," <i>The Journal of Immunology</i> , 136: No. 7, 2456-2462, April 1, 1986
attached	Novogrodsky, et al., "Hydroxyl radical scavengers inhibit lymphocyte mitogenesis" <i>Proc. Natl. Acad. Sci. USA</i> , 79:1171-1174 (1982).
ArH	Okamoto, et al., "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells," <i>Immunology</i> , 70: 186-190, 1990
ArH	Osband, et al., "Successful Tumour Immunotherapy with Cimetidine in Mice," <i>The Lancet</i> , No. 8221, 1: 636-638 (1981).
ArH	Østensen, et al., "Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor or Interleukin-1 and Interferon- or Interleukin-2," <i>Journal of Biological Response Modifiers</i> , 8: 53-61, 1989.
ArH	Phillips, et al., "Activation of Natural Killer Cells via the p75 Interleukin 2 Receptor," <i>J. Exp. Med.</i> , 170: 291-296, July 1989.
ArH	Pignol, et al., "Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response," <i>Plant Flavonoids in Biology & Medicine II: Biochemical, Cellular . . .</i> , 173-182, 1988.
ArH	Rabilloud, et al., "Deficiency in Catalase Activity Correlates with the Appearance of Tumor Phenotype in Human Keratinocytes," <i>Int. J. Cancer</i> , 45: 952-956, 1990.
ArH	Richtsmeier, et al., "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," <i>Ann Otol Rhinol Laryngol</i> , 96: No. 5, 569-572, 1987.
ArH	Rosenberg, "The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2," <i>Annals of Surgery</i> , 208: No. 2, 121-135, August 1988.
ArH	Roth, et al., "Inhibition of Lymphokine-activated Killer Cell Function by Human Alveolar Macrophages," <i>Cancer Research</i> , 49: 4690-4695, September 1989.
ArH	Saarloos, et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stem Cells," <i>Cancer Research</i> , 52: 6452-6462, December 1, 1992.
ArH	Saarloos, et al., "Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis," <i>Clin. Exp. Metastasis</i> , 11: 275-283, 1993.
ArH	Salup, et al., "Chemoimmunotherapy of Metastatic Murine Renal Cell Carcinoma Using Flavone Acetic Acid and Interleukin 2," <i>The Journal of Urology</i> , 147: 1120-1123, April 1992.
ArH	Schantz, et al., "A phase II study of interleukin-2 and interferon-alpha in head and neck cancer," <i>Investigational New Drugs</i> , 10: 217-223, 1992.
ArH	Schleimer, et al., "Regulation of Human Basophil Mediator Release by Cytokines," <i>The Journal of Immunology</i> , 143: No. 4, 1310-1317, August 15, 1989.
ArH	Seaman, et al., "Suppression of Natural Killing In Vitro by Monocytes and Polymorphonuclear Leukocytes," <i>The Journal of Clinical Investigation</i> , 69: 876-888, April 1982.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 808; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

NOT AVAILABLE COPY

JAN 07 2005

SHEET 8 OF 8

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MAXIM 28CS
TRADEMARKSAPPLICATION NO.
UnknownINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hellstrand, et al.FILING DATE
February 12, 2002GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ALH	Shau, et al., "Inhibition of Lymphokine-Activated Killer- and Natural Killer-Mediated Cytotoxicities by Neutrophils," <i>The Journal of Immunology</i> , 143: No. 3, 1066-1072, August 1989.
ALH	Siegel, et al., "The IL-2 Receptor Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities," <i>Science</i> , Volume 238, October 2, 1987
ALH	Sleijfer, et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1119-1123, July 1992.
ALH	Sone, et al., "Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients" <i>Cancer Immunol Immunother.</i> 30:357-362 (1990).
ALH	Stoter, et al., "Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastatic Melanoma: A Multicenter Phase II Study," <i>Journal of Clinical Oncology</i> , 9: No. 9, 1687-1691, September 1991.
ALH	Suthanthiran, et al., "Hydroxyl radical scavengers inhibit human natural killer cell activity," <i>Nature</i> 307: 276-278, (1984).
ALH	Szatrowski, et al., "Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells," <i>Cancer Research</i> , 51: 794-798, February 1991.
ALH	Tel-Or, et al., "Hydroperoxide Metabolism in Cyanobacteria," <i>Archives of Biochemistry and Biophysics</i> , 246: No. 1, 396-402, April 1986.
ALH	Thompson, et al., "Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 6, 960-968, June 1992.
ALH	Thornes, et al., "Combination of Cimetidine with other Drugs for Treatment of Cancer," <i>New England Journal of Medicine</i> 308: 591-592, March 10, 1983.
ALH	Tom Smith, MD, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy," <i>Comprehensive Therapy</i> , 16: No. 1, 8-13, 1990.
ALH	Tracy, et al., "Immunological Effects of Flavone Acetic Acid," <i>Cancer Research</i> , 50: 6483-6485, October 15, 1990.
ALH	Urba, et al., "Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid," <i>The Journal of the National Cancer Institute</i> , 80: No. 7, 521-525, June 1, 1988.
ALH	Weiss, et al., "A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 2, 275-281, February 1992.
ALH	Whitacre, et al., "Oxygen Free Radical Generation and Regulation of Proliferative Activity of Human Mononuclear Cells Responding to Different Mitogens," <i>Cellular Immunology</i> , 144: 287-295, 1992.
ALH	Wiltout, et al., "Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer," <i>The Journal of Immunology</i> , 140: No. 9, 3261-3265, May 1, 1988.

S:\DOCS\UJMJM-3822.DOC

051500

S:\DOCS\WKDWMKD-2500.DOC

021202

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 808; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

BEST AVAILABLE COPY

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
	APPLICANT Hellstrand, et al.	
	FILING DATE February 12, 2002	GROUP Unknown 1642

 11046 U.S. PTO
 10/076306
 02/12/02

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
ALH	5,348,739	09-1994	Hellstrand et al.			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	JP 7-185582	08/27/95	Japan (with English translation in 15 pages)				
ALH	WO 83/24144	12/09/93	Patent Cooperation Treaty				
	0 247 813 A2	12/02/87	European Patent Office				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ALH	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
ALH	Abrams, et al., "igh-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- γ , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- α , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
	Abrams, et al., "igh-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
ALH	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- γ , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- α , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
ALH	Baker, et al., "Chondrocyte Antioxidant Defenses: The Roles of Catalase and Glutathione Peroxidase in Protection Against H ₂ O ₂ Dependent Inhibition of Proteoglycan Biosynthesis," <i>The Journal of Rheumatology</i> , 15: No. 4, 670-677, 1988.
ALH	Barna, et al., "Tumor-Enhancing Effects of Cimetidine," <i>Oncology</i> , 40: 43-45, (1983).
ALH	Beer, et al., The Influence of Histamine on Immune and Inflammatory Responses, <i>Advances in Immunology</i> , 35: 209-268 (1984).

EXAMINER	<i>Harmon A. Gamble</i>	DATE CONSIDERED	10/31/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

BEST AVAILABLE COPY

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Brune, et al., "Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia," <i>British Journal of Haematology</i> , 92:620-626 (1996).
ALH	Budd, et al., "Phase I Trial of High-Dose Bolus Interleukin-2 and Interferon Alfa-2a in Patients With Metastatic Malignancy," <i>Journal of Clinical Oncology</i> , 10: No. 5, 804-809, May 1992.
ALH	Burtin, et al., "Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H2-Antihistaminics" (Ranitidine or Cimetidine), Accepted June 1987.
	Burtin, et al., "The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice", <i>Cancer Letters</i> , 12: 195-201, (1981).
	Chaudhri, et al., "Antioxidants Inhibit Proliferation and Cell Surface Expression of Receptors for Interleukin-2 and Transferrin in T Lymphocytes Stimulated with Phorbol Myristate Acetate and Ionomycin" <i>Cellular Immunology</i> , 115:204-213 (1988).
ALH	Chehimi, et al., "Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-infected Patients," <i>Journal of Experimental Medicine</i> , 175: 789-796, March 1992.
ALH	Ching, et al., "In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthene Analogues of Flavone Acetic Acid," <i>Eur. J. Cancer</i> , 27: No. 12, 1684-1689, 1991.
ALH	Ching, et al., "Induction of Natural Killer Activity by Xanthene Analogues of Flavone Acetic Acid: Relation with Antitumour Activity," <i>Eur. J. Cancer</i> , 27: No. 1, 79-83, 1991.
ALH	Damia, et al., "Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells," <i>Cancer Immunol Immunother</i> , 32: 241-244, 1990.
ALH	Davies, et al., "Interactions between human monocytes and tumor cells. Monocytes can either enhance or inhibit the growth and survival of K562 Cells," November 1991.
ALH	Dempsey, et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity," <i>The Journal of Immunology</i> , May 17, 1982.
ALH	Dillman, et al., "Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial," <i>Journal of Clinical Oncology</i> , 9: No. 7, 1233-1240, July 1991.
ALH	Dilman, et al., "Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial," <i>Journal of the National Cancer Institute</i> , 82: No. 16, 1345-1348, August 15, 1990.
ALH	Dohlsten, et al., "Histamine Inhibits Interferon- Production via Suppression of Interleukin 2 Synthesis," <i>Cellular Immunology</i> , 101: 493-501, 1986.
ALH	Dröge, et al., "Effect of Reactive Oxygen Intermediates and Antioxidants on Proliferation and Function of T Lymphocytes" <i>Methods in Enzymology</i> , 234:135-151 (1994).
ALH	Dröge, et al., "Histamine Augments Interleukin-2 Production and the Activation of Cytotoxic T Lymphocytes," <i>Immunopharmacology</i> , 11: 1-6, 1986.
ALH	Dutcher, et al., "A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients With Metastatic Melanoma," <i>Journal of Clinical Oncology</i> , 9: No. 4, 641-648, April 1991..

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

BEST AVAILABLE COPY

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ArH	Duwe, et al., "Natural Killer Cell-Mediated Lysis Involves an Hydroxyl Radical-Dependent Step," <i>The Journal of Immunology</i> , 134: No. 4, 2637-2644, April 1985.
ArH	El-Hag, et al., "Down-Regulation of Human Natural Killer Activity Against Tumors by the Neutrophil Myeloperoxidase System and Hydrogen Peroxide," <i>The Journal of Immunology</i> 133: No. 6, 3291-3297, December 1984.
	Froelich, et al., "Induction of lymphokine activated killer cells in serum-free medium" <i>Journal of Immunological Methods</i> , 86:205-211, No. 2 (1986).
ArH	Galligioni, "Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with Flavone acetic acid (FAA)," <i>Annals of Oncology</i> , 2: 145-150, 1991.
ArH	Hellstrand, "Biogenic Amines in the Regulation of Human Natural Killer Cell Cytotoxicity," 1987.
	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
ArH	Hellstrand, et al., "A Cell-to-Cell Mediated Interaction Involving Monocytes and Non-T/CD16 ⁺ Natural Killer (NK) Cells is Required for Histamine H ₂ -Receptor-Mediated NK-Cell Activation," <i>Scand J. Immunol</i> , 31: 631-644, 1990.
ArH	Hellstrand, et al., "Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H ₂ -Receptors," <i>Scand J. Immunol</i> , 34: 741-752, 1991..
ArH	Hellstrand, et al., "Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Cell Activity," <i>Int. Archs Allergy appl. Immunology</i> , 84: 247-255, 1987.
ArH	Hellstrand, et al., "Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD16 ⁺ NK Cells, Accessory Monocytes, and 5-HT _{1A} Receptors," <i>Cellular Immunology</i> , 127: 199-214, 1990.
ArH	Hellstrand, et al., "Histamine H ₂ -Receptor-Mediated Regulation of Human Natural Killer Cell Activity," <i>The Journal of Immunology</i> , 137: No. 2, July 15, 1986.
ArH	Hellstrand, et al., "Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H ₂ -Receptors," <i>Cellular Immunology</i> , 138: 44-45, 1991..
ArH	Hellstrand, et al., "Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation," <i>Scand J. Immunol</i> , 32: 183-192, 1990.
ArH	Hellstrand, et al., "Regulation of the Natural Killer Cell Response to Interferon- by Biogenic Amines," <i>Journal of Interferon Research</i> , 12: 199-206, 1992.
ArH	Hellstrand, et al., "Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells," <i>The Journal of Immunology</i> , 145: No. 12, December 15, 1990.
ArH	Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," <i>The Journal of Immunology</i> , 139: No. 3, August 1, 1987
ArH	Hellstrand, et al., "Serotonergic 5-HT _{1A} Receptors Regulate a Cell Contact-Mediated Interaction between Natural Killer Cells and Monocytes," <i>Scand J. Immunol</i> , 37: 7-18, 1993
	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
ArH	Hellstrand, et al., "Suppression of human natural killer cell cytotoxicity by interleukin-2," <i>Clin. Exp. Immunol</i> , 77: 410-416, 1989

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
	APPLICANT Hellstrand, et al.	
	FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Aut	Hellstrand, et al., "Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2," <i>Int. Arch. Allergy Appl. Immunology</i> , 92: 379-389, 1990.
	Histamine augments interleukin-2 production and the activation of cytotoxic T lymphocytes, <i>Chemical Abstracts</i> , 104: Number 146898m, page 146891.
Aut	Hornung, et al., "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2," <i>The Journal of Immunology</i> , 141: No. 10, 3671-3679, November 15, 1988.
Aut	Huwylar, et al., "Effect of Ascorbic Acid on Human Natural Killer Cells," <i>Immunology Letters</i> , 10: 173-176, 1985.
Aut	Ibson, et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients With Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1124-1130, July 1992.
Aut	Kendall A. Smith, "Interleukin-2: Inception, Impact, and Implications," <i>Science</i> , 240: 1169-1176, May 27, 1988.
Aut	Kessel, et al., "Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations," <i>Immunology</i> , 58: 291-296, 1986.
Aut	Khoo, et al., "Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2," <i>Clin. Exp. Metastasis</i> , 10: 239-252, 1992.
Aut	Krigel, et al., "enal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon," <i>Journal of Clinical Oncology</i> , 8: No. 3, 460-467, March 1990.
Aut	Lasek, et al., "Potentiation of antitumor effects of tumor necrosis factor γ and interferon (by macrophage-colony-stimulating factor in a MnB16 melanoma model in mice" <i>Cancer Immunol Immunother</i> 40:315-321 (1995).
Aut	Lespinat, et al., "Enhancement by serotonin of intra-tumour penetration of spleen cells," <i>Br. J. Cancer</i> , 50: 545-547 (1984).
	Los, et al., "Hydrogen peroxide as a potent activator of T lymphocyte functions" <i>Eur. Journal of Immunology</i> , 25:159-165 (1995).
Aut	Lotze, et al., "Interleukin 2 as a Pharmacologic Reagent, Chapter 12 from the National Institutes of Health," October 28, 1988.
	Malech, et al., "Peptide derivative cytochrome inhibit enzyme system oxidation burst phagocyte cell inflammation disease" DABASE WPI/DERWENT (Abstract) (1989).
Aut	Mavligit, et al., "plenit Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases," <i>Journal of Clinical Oncology</i> , 8: No. 2, 319-324, 1990.
Aut	Mertens, et al., "Sustained Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A Phase II Study," <i>Clinical Oncology</i> , 5: No. 2, 107-113, 1993.
Aut	Middleton, et al., "Effects of Flavonoids on Immune and Inflammatory Cell Functions," <i>Biochemical Pharmacology</i> , 43: No. 6, 1167-1179, 1992.
Aut	Munakata, et al., "Induction of Interferon- Production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide," <i>The Journal of Immunology</i> , 134: No. 4, 2449-2455, April 1985.

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

SCIENCE

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ArH	Nabil Hanna, "The Role of Natural Killer Cells in the Control of Tumor Growth and Metastasis," <i>Biochimica et Biophysica Acta</i> , 780: 213-226, 1985.
ArH	Nair, et al., "Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2," <i>The Journal of Immunology</i> , 136: No. 7, 2456-2462, April 1, 1986
	Novogrodsky, et al., "Hydroxyl radical scavengers inhibit lymphocyte mitogenesis" <i>Proc. Natl. Acad. Sci. USA</i> , 79:1171-1174 (1982).
ArH	Okamoto, et al., "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells," <i>Immunology</i> , 70: 186-190, 1990
ArH	Osband, et al., "Successful Tumour Immunotherapy with Cimetidine in Mice," <i>The Lancet</i> , No. 8221, 1: 636-638 (1981).
ArH	Østensen, et al., "Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor or Interleukin-1 and Interferon- or Interleukin-2," <i>Journal of Biological Response Modifiers</i> , 8: 53-61, 1989.
ArH	Phillips, et al., "Activation of Natural Killer Cells via the p75 Interleukin 2 Receptor," <i>J. Exp. Med.</i> , 170: 291-296, July 1989.
ArH	Pignol, et al., "Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response," <i>Plant Flavonoids in Biology & Medicine II: Biochemical, Cellular . . .</i> , 173-182, 1988.
ArH	Rabilloud, et al., "Deficiency in Catalase Activity Correlates with the Appearance of Tumor Phenotype in Human Keratinocytes," <i>Int. J. Cancer</i> , 45: 952-956, 1990.
ArH	Richtsmeier, et al., "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," <i>Ann Otol Rhinol Laryngol</i> , 96: No. 5, 569-572, 1987.
ArH	Rosenberg, "The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2," <i>Annals of Surgery</i> , 208: No. 2, 121-135, August 1988.
ArH	Roth, et al., "Inhibition of Lymphokine-activated Killer Cell Function by Human Alveolar Macrophages," <i>Cancer Research</i> , 49: 4690-4695, September 1989.
ArH	Saarloos, et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stem Cells," <i>Cancer Research</i> , 52: 6452-6462, December 1, 1992.
ArH	Saarloos, et al., "Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis," <i>Clin. Exp. Metastasis</i> , 11: 275-283, 1993.
ArH	Salup, et al., "Chemoimmunotherapy of Metastatic Murine Renal Cell Carcinoma Using Flavone Acetic Acid and Interleukin 2," <i>The Journal of Urology</i> , 147: 1120-1123, April 1992.
ArH	Schantz, et al., "A phase II study of interleukin-2 and interferon-alpha in head and neck cancer," <i>Investigational New Drugs</i> , 10: 217-223, 1992.
ArH	Schleimer, et al., "Regulation of Human Basophil Mediator Release by Cytokines," <i>The Journal of Immunology</i> , 143: No. 4, 1310-1317, August 15, 1989.
ArH	Seaman, et al., "Suppression of Natural Killing in Vitro by Monocytes and Polymorphonuclear Leukocytes," <i>The Journal of Clinical Investigation</i> , 69: 876-888, April 1982.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Helstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ALH	Shau, et al., "Inhibition of Lymphokine-Activated Killer- and Natural Killer-Mediated Cytotoxicities by Neutrophils," <i>The Journal of Immunology</i> , 143: No. 3, 1066-1072, August 1989.
ALH	Siegel, et al., "The IL-2 Receptor Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities," <i>Science</i> , Volume 238, October 2, 1987
ALH	Sleijfer, et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1119-1123, July 1992.
ALH	Sone, et al., "Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients" <i>Cancer Immunol Immunother.</i> 30:357-362 (1990).
ALH	Stoter, et al., "Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastatic Melanoma: A Multicenter Phase II Study," <i>Journal of Clinical Oncology</i> , 9: No. 9, 1687-1691, September 1991.
ALH	Suthanthiran, et al., "Hydroxyl radical scavengers inhibit human natural killer cell activity," <i>Nature</i> 307: 276-278, (1984).
ALH	Szatrowski, et al., "Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells," <i>Cancer Research</i> , 51: 794-798, February 1991.
ALH	Tel-Or, et al., "Hydroperoxide Metabolism in Cyanobacteria," <i>Archives of Biochemistry and Biophysics</i> , 246: No. 1, 396-402, April 1986.
ALH	Thompson, et al., "Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 6, 960-968, June 1992.
ALH	Thornes, et al., "Combination of Cimetidine with other Drugs for Treatment of Cancer," <i>New England Journal of Medicine</i> 308: 591-592, March 10, 1983.
ALH	Tom Smith, MD, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy," <i>Comprehensive Therapy</i> , 16: No. 1, 8-13, 1990.
ALH	TK 0221 Tren, et al., "Immunological Effects of Flavone Acetic Acid," <i>Cancer Research</i> , 50: 6483-6485, October 15, 1990.
ALH	Urba, et al., "Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid," <i>The Journal of the National Cancer Institute</i> , 80: No. 7, 521-525, June 1, 1988.
ALH	Weiss, et al., "A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 2, 275-281, February 1992.
ALH	Whitacre, et al., "Oxygen Free Radical Generation and Regulation of Proliferative Activity of Human Mononuclear Cells Responding to Different Mitogens," <i>Cellular Immunology</i> , 144: 287-295, 1992.
ALH	Wiltout, et al., "Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer," <i>The Journal of Immunology</i> , 140: No. 9, 3261-3265, May 1, 1988.

S:\DOCS\JM\JM-3822.DOC
051500
S:\DOCS\MKD\MKD-2500.DOC
021202

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.026C3	APPLICATION NO. 10/078,308
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand et al.	
		FILING DATE February 12, 2002	GROUP 1642



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PH	1	Bacon et al. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. Journal of Experimental Medicine. 181:399-404.
PH	2	Nelson et al. (1998) Biology of the interleukin-2 receptor. Advances in Immunology. 70:1-81.
PH	3	Presky et al. (1996) A functional interleukin 12 receptor complex is composed of two β -type cytokine receptor subunits. Proc. Natl. Acad. Sci. 93:14002-14007.
PH	4	Wolf et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology. 146(9):3074-3081.

S:\DOCS\WKD\MKD-4082.DOC\021904

EXAMINER	Anne L. Hollman	DATE CONSIDERED	9/30/2004
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.026C3	APPLICATION NO. 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand et al.	
		FILING DATE February 12, 2002	GROUP 1642



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bacon et al. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. Journal of Experimental Medicine. 181:399-404.
	2	Nelson et al. (1998) Biology of the interleukin-2 receptor. Advances in Immunology. 70:1-81.
	3	Presky et al. (1996) A functional interleukin 12 receptor complex is composed of two β -type cytokine receptor subunits. Proc. Natl. Acad. Sci. 93:14002-14007.
	4	Wolf et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology. 146(9):3074-3081.

S:\DOCS\MKD\MKD-4082.DOC\021904

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	